Differential changes in the pharmacokinetics of doxorubicin in diethylnitrosamine-induced hepatocarcinoma model rats

References

• Afzal M, Kazmi I, Khan R, et al. (2017). Thiamine potentiates chemoprotective effects of ibuprofen in DEN induced hepatic cancer via alteration of oxidative stress and inflammatory mechanism. Arch Biochem Biophys 623–624:58–63.
   PubMed Web of Science ®Google Scholar
• Ashtari S, Pourhoseingholi MA, Sharifian A, Zali MR. (2015). Hepatocellular carcinoma in Asia: prevention strategy and planning. World J Hepatol 7:1708–17.
   PubMed Web of Science ®Google Scholar
• Bradley G, Ling V. (1994). P-glycoprotein, multidrug resistance and tumor progression. Cancer Metastasis Rev 13:223–33.
   PubMed Web of Science ®Google Scholar
• Bralet MP, Pichard V, Ferry N. (2002). Demonstration of direct lineage between hepatocytes and hepatocellular carcinoma in diethylnitrosamine-treated rats. Hepatology 36:623–30.
   PubMed Web of Science ®Google Scholar
• Binkhathlan Z, Shayeganpour A, Brocks DR, Lavasanifar A. (2012). Encapsulation of P-glycoprotein inhibitors by polymeric micelles can reduce their pharmacokinetic interactions with doxorubicin. Eur J Pharm Biopharm 81:142–8.
   PubMed Web of Science ®Google Scholar
• Chen H, Shen ZY, Xu W, et al. (2014). Expression of P450 and nuclear receptors in normal and end-stage Chinese livers. World J Gastroenterol: WJG 20:8681–90.
   PubMed Web of Science ®Google Scholar
• Colombo T, Zucchetti M, Incalci MD. (1994). Cyclosporin a markedly changes the distribution of doxorubicin in mice and rats. J Pharmacol Exp Ther 269:22–7.
   PubMed Web of Science ®Google Scholar
• Eusuf DV, Thomas E. (2019). Pharmacokinetic variation. Anaesth Intensive Care Med 20:126–9.
   Web of Science ®Google Scholar
• Faraji A, Manshadi HRD, Mobaraki M, et al. (2016). Association of ABCB1 and SLC22A16 gene polymorphisms with incidence of doxorubicin-induced febrile neutropenia: a survey of Iranian breast cancer patients. Plos One 11:e0168519.
   PubMed Web of Science ®Google Scholar
• Ferreira A, Cunha-Oliveira T, Simões RF, et al. (2017). Altered mitochondrial epigenetics associated with subchronic doxorubicin cardiotoxicity. Toxicology 390:63–73.
   PubMed Web of Science ®Google Scholar
• Fritz P, Behrle E, Beaune P, et al. (1993). Differential expression of drug metabolizing enzymes in primary and secondary liver neoplasm: immunohistochemical characterization of cytochrome P4503A and glutathione-S-transferase. Histochem Cell Biol 99:443–51.
   Google Scholar
• Fukuda H, Ebara M, Okuyama M, et al. (2002). Increased metabolizing activities of the tricarboxylic acid cycle and decreased drug metabolism in hepatocellular carcinoma. Carcinogenesis 23:2019–23.
   PubMed Web of Science ®Google Scholar
• Gao B, Yang FM, Yu ZT, et al. (2015). Relationship between the expression of MDR1 in hepatocellular cancer and its biological behaviors. Int J Clin Exp Pathol 8:6995.
   PubMed Web of Science ®Google Scholar
• Gao J, Zhou J, He XP, et al. (2016). Changes in cytochrome P450s-mediated drug clearance in patients with hepatocellular carcinoma in vitro and in vivo: a bottom-up approach. Oncotarget 7:28612–23.
   PubMed Web of Science ®Google Scholar
• Golam K, Hiroto H, Kosuke A, et al. (2014). Comparative study of the sensitivities of cancer cells to doxorubicin, and relationships between the effect of the drug-efflux pump P-gp. Biol Pharm Bull 37:1926–35.
   PubMed Web of Science ®Google Scholar
• Hodges LM, Markova SM, Chinn LW, et al. (2011). Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genom 21:152–61.
   PubMed Web of Science ®Google Scholar
• Jiang B, Yan L, Wu Q. (2019). ABCB1 (C1236T) polymorphism affects P-glycoprotein-mediated transport of methotrexate, doxorubicin, actinomycin D, and etoposide. DNA Cell Biol 38:485–6.
   PubMed Web of Science ®Google Scholar
• Jin X, Qian C, Du X, et al. (2009). Pathologic and morphologic study on modified DEN-induced hepatocarcinoma model in rats. China J Modern Med 19:2593–6.
   Google Scholar
• Jo A, Choi TG, Jo YH, et al. (2017). Inhibition of carbonyl reductase 1 safely improves the efficacy of doxorubicin in breast cancer treatment. Antioxid Redox Signal 26:70–83.
   PubMed Web of Science ®Google Scholar
• Kassner N, Huse K, Martin HJ, et al. (2008). Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. Drug Metab Dispos 36:2113–20.
   PubMed Web of Science ®Google Scholar
• Khan F, Khan TJ, Kalamegam G, et al. (2017). Anti-cancer effects of Ajwa dates (Phoenix dactylifera L.) in diethylnitrosamine induced hepatocellular carcinoma in Wistar rats. BMC Complement Altern Med 17:418.
   PubMed Web of Science ®Google Scholar
• Kot M. (2015). The role of the serotonergic system in the regulation of cytochrome P450 during hepatocarcinogenesis. Toxicol Lett 238:S237.
   Web of Science ®Google Scholar
• Krekels EHJ, Rower JE, Constance JE, et al. (2017). Chapter 8 – Hepatic drug metabolism in pediatric patients. In: Xie W, ed. Drug metabolism in disease. Cambridge: Academic Press, p. 181–206.
   Google Scholar
• Liu F, Wang P, Jiang X, et al. (2008). Antisense hypoxia-inducible factor 1α gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma. Cancer Sci 99:2055–61.
   PubMed Web of Science ®Google Scholar
• Lončar-Turukalo T, Vasić M, Tasić T, et al. (2015). Heart rate dynamics in doxorubicin-induced cardiomyopathy. Physiol Meas 36:727–39.
   PubMed Web of Science ®Google Scholar
• McCormick JW, Vogel PD, Wise JG. (2015). Multiple drug transport pathways through human P-glycoprotein. Biochemistry 54:4374–90.
   PubMed Web of Science ®Google Scholar
• Mordente A, Minotti G, Martorana GE, et al. (2003). Anthracycline secondary alcohol metabolite formation in human or rabbit heart: biochemical aspects and pharmacologic implications. Biochem Pharmacol 66:989–98.
   PubMed Web of Science ®Google Scholar
• Okabe M, Unno M, Harigae H, et al. (2005). Characterization of the organic cation transporter SLC22A16: a doxorubicin importer. Biochem Biophys Res Commun 333:754–62.
   PubMed Web of Science ®Google Scholar
• Ota K, Ito K, Akahira JI, et al. (2007). Expression of organic cation transporter SLC22A16 in human epithelial ovarian cancer: a possible role of the adriamycin importer. Int J Gynecol Pathol 26:334–40.
   PubMed Web of Science ®Google Scholar
• Patel KJ, Tannock IF. (2009). The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors. BMC Cancer 9:356.
   PubMed Web of Science ®Google Scholar
• Ramsden D, Smith D, Arenas R, et al. (2018). Identification and characterization of a selective human carbonyl reductase 1 substrate. Drug Metab Dispos 46:1434–40.
   PubMed Web of Science ®Google Scholar
• Rivankar S. (2014). An overview of doxorubicin formulations in cancer therapy. J Cancer Res Ther 10:853–8.
   PubMed Web of Science ®Google Scholar
• Sauzay C, Petit A, Bourgeois AM, et al. (2016). Alpha-foetoprotein (AFP): a multi-purpose marker in hepatocellular carcinoma. Clin Chim Acta 463:39–44.
   PubMed Web of Science ®Google Scholar
• Shi SM, Di L. (2017). The role of carbonyl reductase 1 in drug discovery and development. Expert Opin Drug Metabol Toxicol 13:859–70.
   PubMed Web of Science ®Google Scholar
• Thakkar N, Slizgi JR, Brouwer KLR. (2017). Effect of liver disease on hepatic transporter expression and function. J Pharm Sci 106:2282–94.
   PubMed Web of Science ®Google Scholar
• Travis CC, McClain TW, Birkner PD. (1991). Diethylnitrosamine-induced hepatocarcinogenesis in rats: a theoretical study. Toxicol Appl Pharmacol 109:289–304.
   PubMed Web of Science ®Google Scholar
• Wang M, Devarajan K, Singal AG, et al. (2016). The Doylestown algorithm: a test to improve the performance of AFP in the detection of hepatocellular carcinoma. Cancer Prev Res 9:172–9.
   PubMed Web of Science ®Google Scholar
• Wang X, Hui R, Chen Y, et al. (2019). Discovery of novel doxorubicin metabolites in MCF7 doxorubicin-resistant cells. Front Pharmacol 10:1434.
   PubMed Web of Science ®Google Scholar
• Yan T, Gao S, Peng X, et al. (2015). Significantly decreased and more variable expression of major CYPs and UGTs in liver microsomes prepared from HBV-positive human hepatocellular carcinoma and matched pericarcinomatous tissues determined using an isotope label-free UPLC–MS/MS method. Pharm Res 32:1141–57.
   PubMed Web of Science ®Google Scholar
• Yang Y, Zhang JP, Wu T, et al. (2019). Histone deacetylase 2 regulates the doxorubicin (Dox) resistance of hepatocarcinoma cells and transcription of ABCB1. Life Sci 216:200–6.
   PubMed Web of Science ®Google Scholar
• Ye L, Yang X, Guo E, et al. (2014). Sorafenib metabolism is significantly altered in the liver tumor tissue of hepatocellular carcinoma patient. Plos One 9:e96664.
   PubMed Web of Science ®Google Scholar
• Zhong J, Sun P, Xu N, et al. (2020). Canagliflozin inhibits p-gp function and early autophagy and improves the sensitivity to the antitumor effect of doxorubicin. Biochem Pharmacol 175:113856.
   PubMed Web of Science ®Google Scholar
• Zhuo SY, Fang ZQ, Guan D, et al. (2008). Expression characteristics of cytochrome superfamily genes during diethylnitrosamine-induced hepatocarcino-genesis in rats. China Tumor 17:874–7.
   Google Scholar